Zydus Receives USFDA EIR for Baddi Facility
Zydus Lifesciences has announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drugs Administration (USFDA) for its manufacturing facility in Baddi.
The inspection, which took place from August 4th to 13th, 2025, resulted in four observations, and the facility has been classified as Voluntary Action Indicated (VAI).
The USFDA has concluded the inspection as closed.
The EIR has classified the facility as Voluntary Action Indicated (VAI).
Zydus Lifesciences Ltd. is a global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
Author's summary: Zydus receives USFDA report.